DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.

@article{Trinh2016DNM3AG,
  title={DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.},
  author={Joanne Trinh and Emil K Gustavsson and Carles Vilari{\~n}o-G{\"u}ell and Stephanie F Bortnick and Jeanne Latourelle and Marna B. McKenzie and Chelsea Szu Tu and Ekaterina Nosova and Jaskaran Khinda and Austen J Milnerwood and Suzanne R Lesage and Alexis Brice and M{\'e}riem Tazir and Jan O Aasly and L Parkkinen and Hazal Haytural and Tatiana Foroud and Richard H. Myers and Samia Ben Sassi and Emna Hentati and Fatma Nabli and Emna Farhat and Rim Amouri and Fayçal Hentati and Matthew J Farrer},
  journal={The Lancet. Neurology},
  year={2016},
  volume={15 12},
  pages={
          1248-1256
        }
}
BACKGROUND Leucine-rich repeat kinase 2 (LRRK2) mutation 6055G→A (Gly2019Ser) accounts for roughly 1% of patients with Parkinson's disease in white populations, 13-30% in Ashkenazi Jewish populations, and 30-40% in North African Arab-Berber populations, although age of onset is variable. Some carriers have early-onset parkinsonism, whereas others remain asymptomatic despite advanced age. We aimed to use a genome-wide approach to identify genetic variability that directly affects LRRK2… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…